Evaluation of Correlations Between Volatile Organic Compounds and Venous Blood Glucose in Subjects With Type 2 Diabetes
Launched by DCB RESEARCH AG ยท
Trial Information
Current as of September 25, 2025
Recruiting
Keywords
ClinConnect Summary
This study is looking at whether certain chemicals in the breath, called volatile organic compounds (VOCs), are linked to blood sugar levels in people with Type 2 Diabetes. Researchers want to see if changes in these breath chemicals match changes in blood sugar when it goes up or down. To do this, they will use special machines to measure VOCs and compare these results with blood sugar tests taken from veins.
People with Type 2 Diabetes who are between about 35 and 66 years old can take part. During the study, participants will have their blood sugar levels changed in a few ways: by drinking a sugary drink, receiving insulin, or eating a meal. Throughout this time, their breath and blood sugar will be tested to see how they relate. This research could help develop easier, non-invasive ways to monitor blood sugar in the future.
Gender
ALL
Eligibility criteria
About Dcb Research Ag
DCB Research AG is a forward-thinking clinical trial sponsor specializing in the design and management of innovative clinical studies across various therapeutic areas. With a commitment to advancing medical research, DCB Research AG leverages cutting-edge methodologies and technology to enhance trial efficiency and data integrity. The organization collaborates closely with healthcare professionals, regulatory bodies, and industry partners to ensure the highest standards of compliance and ethical practices. Through its dedicated team of experts, DCB Research AG aims to contribute significantly to the development of new therapies that improve patient outcomes and foster advancements in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Frank Flacke, Dr.
Study Chair
BOYDSense SAS
Markus Laimer, Dr. med
Principal Investigator
Inselspital Bern, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported